| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CHMFL-PI3KD-317 manufacturers
- CHMFL-PI3KD-317
-
- $93.00
-
2026-07-27
- CAS:2244992-76-3
- Purity: 99.16%
- Supply Ability: 10g
- CHMFL-PI3KD-317
-
- $93.00
-
2026-07-27
- CAS:2244992-76-3
- Purity: 99.16%
- Supply Ability: 10g
|
| | CHMFL-PI3KD-317 Basic information |
| Product Name: | CHMFL-PI3KD-317 | | Synonyms: | CHMFL-PI3KD-317;CHMFL-PI-3KD-317,CHMFLPI3KD317,CHMFL PI3KD 317;Butanamide, 2-amino-N-[5-[6-chloro-5-[[(3-methylphenyl)sulfonyl]amino]-3-pyridinyl]-4-methyl-2-thiazolyl]-3-methyl-, (2S)-;CHMFL-PI3KD-317, 10 mM in DMSO;(S)-2-Amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide | | CAS: | 2244992-76-3 | | MF: | C21H24ClN5O3S2 | | MW: | 494.03 | | EINECS: | | | Product Categories: | | | Mol File: | 2244992-76-3.mol |  |
| | CHMFL-PI3KD-317 Chemical Properties |
| density | 1.406±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | form | Solid | | pka | 6.25±0.50(Predicted) | | color | White to off-white |
| | CHMFL-PI3KD-317 Usage And Synthesis |
| Uses | CHMFL-PI3KD-317 is a highly potent, selective and orally active PI3Kδ inhibitor, with an IC50 of 6 nM, and exhibits over 10-1500 fold selectivity over other class I, II and III PIKK family isoforms, such as PI3Kα (IC50, 62.6 nM), PI3Kβ (IC50, 284 nM), PI3Kγ (IC50, 202.7 nM), PIK3C2A (IC50, >10000 nM), PIK3C2B (IC50, 882.3 nM), VPS34 (IC50, 1801.7 nM), PI4KIIIA (IC50, 574.1 nM) and PI4KIIIB (IC50, 300.2 nM). CHMFL-PI3KD-317 inhibits PI3Kδ-mediated Akt T308 phosphorylation in Raji cells, with an EC50 of 4.3 nM. CHMFL-PI3KD-317 has antiproliferative effects on cancer cells[1]. | | in vivo | CHMFL-PI3KD-317 (Compound 15i; 25, 50 and 100 mg/kg/day, p.o., for 14 days) inhibits the growth of the MOLM14 tumor in mice[1].
CHMFL-PI3KD-317 shows favorable oral bioavailability and acceptable half-life (T1/2 = 3.28 h) in Sprague-Dawley rats[1]. | Animal Model: | Female nu/nu mice bearing MOLM-14 tumor xenografts[1] | | Dosage: | 25, 50 and 100mg/kg/day | | Administration: | P.O. for 14 days | | Result: | Inhibited the growth of the MOLM14 tumor without mortality or obvious weight loss in mice. |
| | IC 50 | PI3Kδ: 6 nM (IC50); PI3Kα: 62.6 nM (IC50); PI3Kγ: 202.7 nM (IC50); PI3Kβ: 284 nM (IC50); PIK3C2B: 882.3 nM (IC50); Vps34: 1801.7 nM (IC50); PI4KIIIB: 300.2 nM (IC50); PI4KIIIA: 574.1 nM (IC50) | | References | [1] Liang X, et al. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Eur J Med Chem. 2018 Aug 5;156:831-846. DOI:10.1016/j.ejmech.2018.07.036 |
| | CHMFL-PI3KD-317 Preparation Products And Raw materials |
|